Is the HCV pipeline heading in the right direction?
University of Chicago Medical Center, Department of Medicine, Section of Gastroenterology, Hepatology and Nutrition, Center for Liver Diseases, Chicago, Illinois, USA.
Andrew
A
Aronsohn
Andrew J
AJ
Muir
Tracy
T
Swan
Donald
D
Jensen
D000998:Antiviral Agents / Q000627:therapeutic use*; D060085:Coinfection / Q000175:diagnosis / Q000188:drug therapy; D055808:Drug Discovery / Q000639:trends*; D015658:HIV Infections / Q000150:complications; D006297:Health Services Accessibility; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation; D056687:Off-Label Use; D009842:Oligopeptides / Q000627:therapeutic use; D011392:Proline / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D009842:Oligopeptides; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline